Loading the company…
Loading the company…
Families: CGM & insulin pump management.
All companies · Product and company coverage
In 2025, Tandem Diabetes Care reported engagement with 5,066 surgeons and other clinicians in the states MedaRep covers, worth $719K in consulting, speaking, meals and travel for its device products, the most in Florida ($71K to 422). Royalties are left out.
Spend tied to a procedure counts the payments whose product names it. Open Payments shows the payments companies reported. It suggests engagement, not which devices a surgeon uses, and is not evidence of wrongdoing.Top states by spend: Florida ($71K, 422 engaged), Texas ($63K, 537 engaged), California ($47K, 535 engaged), Michigan ($45K, 99 engaged), Pennsylvania ($44K, 244 engaged).
In the last ten years FDA made 32 decisions for Tandem Diabetes Care (510(k) clearances, De Novo grants, PMA approvals and supplements) under the product codes MedaRep maps to 1 procedure family, the most in 2018 (11). The latest was on 2025-11-06.
| Family | Decisions on record |
|---|---|
| CGM & insulin pump management | 55 |
| Date | Kind | Number | Device |
|---|---|---|---|
| 2025-11-06 | 510(k) | K253074 | Tandem Mobi insulin pump with interoperable technology |
| 2025-09-24 | 510(k) | K250792 | t:slim X2 insulin pump with interoperable technology |
| 2024-07-26 | 510(k) | K241078 | Tandem Mobi Insulin Pump with interoperable technology |
| 2024-03-21 | 510(k) | K240309 | Tandem Mobi insulin pump with interoperable technology |
| 2023-11-03 | 510(k) |
| K232380 |
| t:slim X2 Insulin Pump with Interoperable Technology |
Decisions under the product codes mapped to the procedure families; devices filed under other codes are not here. Applicants are rolled up to Tandem Diabetes Care.